

Meeting Summary

Hexavalent Chromium

Representatives of USEPA and
Hexavalent Chromium Panel (The Policy Group, American Chemistry Council, ToxStrategies)

October 8, 2020 11am-12pm ET

Virtual Meeting

Attendees:

- Behl, Betsy (USEPA, OW)
- Buckley, Timothy (USEPA, ORD)
- Cascio, Wayne (USEPA, ORD)
- Conneely, Eileen (American Chemistry Council)
- Cook, Steven (USEPA, OLEM)
- D'Amico, Louis (USEPA, ORD)
- Dunlap, David (USEPA, ORD)
- Fleming, Megan (USEPA, ORD)
- Foster, Stiven (USEPA, OLEM)
- Gibbons, Catherine (USEPA, ORD)
- Jones, Samantha (USEPA, ORD)
- Miller, Gregory (USEPA, OW)
- Raffaele, Kathleen (USEPA, OLEM)
- Richter, Christian (The Policy Group)
- Rodan, Bruce (USEPA, ORD)
- Sasso, Alan (USEPA, ORD)
- Shams, Dahnish (USEPA, ORD)
- Soto, Vicki (USEPA, ORD)
- Thayer, Kris (USEPA, ORD)
- Thompson, Chad (ToxStrategies)
- Trentacoste, Emily (USEPA, R3)
- Widener, Kelly (USEPA, ORD)
- Wikoff, Daniele (ToxStrategies)

Attachments: EPA Oct 8 2020 – IRIS Cr Post-Meeting with Annotations – Notes Display Version.pdf

Agenda:

1. Introductions
2. Recent Developments since 2016 Meeting
3. Cr(VI) Research Project Update – New Studies in Progress

4. Mode of Action Research to Date – Summary of the Science and Essential Conclusions
5. Authoritative Bodies – Decisions on Toxicity Values
6. Remaining Issues – Systematic Review, Schedule, et al.

Summary:

- Presentation by Chad Thompson (ToxStrategies) - Mode of Action Research for Cr(VI)-Induced Tumors: Overview & Highlight of Select Publications (see slides 1-39).
- Presentation by Danielle Wikoff (ToxStrategies) - Brief discussion on the status mode of action framework proposed in EPA's Systematic Review Protocol for Hexavalent Chromium (see slides 40-44).
- EPA clarifies the anticipated timing of draft Hexavalent Chromium IRIS Assessment timing of the public comment draft – presented in the [IRIS Program Outlook, June \(2020\)](#) as FY21Q4. EPA noted that the next update to the IRIS Program Outlook is scheduled to be published in late October 2020.
- Brief discussion on whether ToxStrategies' proposed Adverse Outcome Pathway (AOP) for small intestinal tumors in mice (manuscript in review) will be submitted for development within the AOP Programme of the Organization for Economic Cooperation and Development (OECD). ToxStrategies researchers will be considering this following publication of the research but notes that the published literature can still serve to inform EPA's IRIS assessment.